<code id='95FE866F4F'></code><style id='95FE866F4F'></style>
    • <acronym id='95FE866F4F'></acronym>
      <center id='95FE866F4F'><center id='95FE866F4F'><tfoot id='95FE866F4F'></tfoot></center><abbr id='95FE866F4F'><dir id='95FE866F4F'><tfoot id='95FE866F4F'></tfoot><noframes id='95FE866F4F'>

    • <optgroup id='95FE866F4F'><strike id='95FE866F4F'><sup id='95FE866F4F'></sup></strike><code id='95FE866F4F'></code></optgroup>
        1. <b id='95FE866F4F'><label id='95FE866F4F'><select id='95FE866F4F'><dt id='95FE866F4F'><span id='95FE866F4F'></span></dt></select></label></b><u id='95FE866F4F'></u>
          <i id='95FE866F4F'><strike id='95FE866F4F'><tt id='95FE866F4F'><pre id='95FE866F4F'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:4
          Courtesy Google DeepMind

          On Tuesday, Google DeepMind and Isomorphic Labs announced a significant progress update on the next iteration of AlphaFold, the deep learning model that in 2020 cracked the problem of predicting a protein’s structure from its amino acid sequence, leapfrogging other approaches in computational biology.

          Now, the companies say they have developed the model to predict not just standalone protein structures, but what proteins look like in combination with several classes of molecules, including small molecules and nucleic acids — capabilities that are key for drug development.

          advertisement

          “We really needed to make progress on protein-ligand binding and co-folding of ligands with proteins in order to help us design more effective drugs,” said Demis Hassabis, CEO of both DeepMind and Isomorphic Labs, which spun out in 2021 with the goal of applying deep learning approaches to drug discovery. The updated model can also predict protein structures after they’ve been modified. “Basically the new AlphaFold can cope with all of these different things, which is pretty amazing.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies
          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

          BiogenCEOChristopherViehbacherSTATTwoyearsafterabigscientificswingnearlypushedBiogentothebrink,CEOCh

          read more
          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more

          ADCs take center stage as promising cancer treatments

          AtESMO2023,antibody-drugconjugateswerefeaturedprominently.AndrewJoseph/STATMADRID—Ifyouhadtopinpoint